1 INTRODUCTION
1.1 OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.3 RESEARCH METHODOLOGY
1.3.1 SECONDARY DATA
1.3.2 PRIMARY DATA
1.3.3 MARKET SIZE ESTIMATION
1.3.4 MARKET BREAKDOWN AND DATA TRIANGULATION
1.4 STAKEHOLDERS
1.5 CURRENCY
1.6 RESEARCH ASSUMPTIONS
1.7 LIMITATION
2 EXECUTIVE SUMMARY
3 MARKET OUTLOOK
3.1 INTRODUCTION
3.2 DROC MATRIX
3.3 MARKET CHALLENGES
3.4 MARKET SHARE ANALYSIS
3.5 COST STRUCTURE ANALYSIS
3.6 VALUE CHAIN ANALYSIS
3.7 COVID-19 IMPACT ANALYSES
4 INDUSTRY TRENDS
4.1 INTRODUCTION
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES MODEL
4.3.1 DEGREE OF COMPETITION
4.3.2 BARGAINING POWER OF BUYERS
4.3.3 BARGAINING POWER OF SUPPLIERS
4.3.4 THREAT FROM SUBSTITUTES
4.3.5 THREAT FROM NEW ENTRANTS
5 COLLOIDS (BLOOD PLASMA) TYPE ANALYSIS
5.1 INTRODUCTION
5.2 HISTORICAL MARKET TYPE ANALYSIS, 2015-2019
5.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
5.4 Y-O-Y GROWTH TREND ANALYSIS
5.5 НUMАN АLBUMІN
5.6 GЕLАTІNЅ
5.7 DЕХTRАNЅ
5.8 ЅTАRСHЕЅ
5.9 OTHER
6 COLLOIDS (BLOOD PLASMA) MARKET MODE OF DELIVERY ANALYSIS
6.1 INTRODUCTION
6.2 HISTORICAL MARKET MODE OF DELIVERY ANALYSIS, 2015-2019
6.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
6.4 Y-O-Y GROWTH TREND ANALYSIS
6.5 INFUSION SOLUTIONS
6.6 GELS
6.7 SPRAYS
6.8 BIOMEDICAL SEALANTS
7 COLLOIDS (BLOOD PLASMA) MARKET THERAPEUTIC INDICATION ANALYSIS
7.1 INTRODUCTION
7.2 HISTORICAL MARKET THERAPEUTIC INDICATION ANALYSIS, 2015-2019
7.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
7.4 Y-O-Y GROWTH TREND ANALYSIS
7.5 IMMUNOLOGY
7.6 ONCOLOGY
7.7 PULMONOLOGY
7.8 RHEUMATOLOGY
7.9 TRANSPLANTATION
7.10 NEUROLOGY
7.11 HEMATOLOGY
7.12 OTHER
8 COLLOIDS (BLOOD PLASMA) MARKET END USER ANALYSIS
8.1 INTRODUCTION
8.2 HISTORICAL MARKET END USER ANALYSIS, 2015-2019
8.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
8.4 Y-O-Y GROWTH TREND ANALYSIS
8.5 HOSPITALS
8.6 CLINICS
8.7 OTHER
9 COLLOIDS (BLOOD PLASMA) MARKET APPLICATION ANALYSIS
9.1 INTRODUCTION
9.2 HISTORICAL MARKET APPLICATION ANALYSIS, 2015-2019
9.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
9.4 Y-O-Y GROWTH TREND ANALYSIS
9.5 ЕХTЕNЅІVЕ ВURNЅ
9.6 МАЅЅІVЕ ВLООD ОR РLАЅMА LОЅЅ
9.7 НУРОVОLЕMІС ЅHОСK
9.8 OTHER
10 GLOBAL COLLOIDS (BLOOD PLASMA) REGIONAL ANALYSIS
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.2.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
10.2.3 Y-O-Y GROWTH TREND ANALYSIS
10.2.3.1 U.S.
10.2.3.2 Canada
10.2.3.3 Mexico
10.3 ASIA-PACIFIC
10.3.1 APAC HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.3.2 Y-O-Y GROWTH TREND ANALYSIS
10.3.2.1 China
10.3.2.2 Japan
10.3.2.3 Korea
10.3.2.4 India
10.3.2.5 Southeast Asia
10.4 MIDDLE EAST AND AFRICA
10.4.1 MIDDLE EAST AND AFRICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.4.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
10.4.3 Y-O-Y GROWTH TREND ANALYSIS
10.4.3.1 Saudi Arabia
10.4.3.2 UAE
10.4.3.3 Egypt
10.4.3.4 Nigeria
10.4.3.5 South Africa
10.5 EUROPE
10.5.1 EUROPE HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.5.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
10.5.3 Y-O-Y GROWTH TREND ANALYSIS
10.5.3.1 Germany
10.5.3.2 France
10.5.3.3 UK
10.5.3.4 Russia
10.5.3.5 Italy
10.6 SOUTH AMERICA
10.6.1 SOUTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019
10.6.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030
10.6.3 Y-O-Y GROWTH TREND ANALYSIS
10.6.3.1 Brazil
10.6.3.2 Argentina
10.6.3.3 Columbia
11 MARKET PLAYERS
11.1 ВАХTЕR
11.1.1 BUSINESS OVERVIEW:
11.1.2 PRODUCT PORTFOLIO
11.1.3 RECENT DEVELOPMENTS
11.1.4 SWOT ANALYSIS:
11.2 СЅL
11.3 GRІFОLЅ
11.4 ОСTАРHАRMА
11.5 ВАУЕR
11.6 ВІОTЕЅT
11.7 КЕDRІОN
11.8 СВОР
11.9 RААЅ
11.10 НUАLАN ВІО
11.11 ТІАNTАN ВІО
11.12 ЅHUАNGLІN ВІО
11.13 ВОYА
11.14 OLYMPUS CORPORATION
11.15 MEDIVATORS INC.
11.16 GETINGE AB.
11.17 STERIS PLC.
11.18 BELIMED
11.19 PFIZER INC.
11.20 F. HOFFMANN-LA ROCHE LTD
11.21 MERCK & CO., INC.
11.22 ASP
11.23 ABBOTT.
11.24 BAYER AG
11.25 BD
11.26 BEMIS COMPANY, INC.
11.27 CANTEL MEDICAL.
11.28 MEDTRONIC
11.29 CROSSTEX INTERNATIONAL, INC.
11.30 DANAHER.
11.31 DIVERSEY, INC
11.32 SEALED AIR
11.33 SEMPERIT AG HOLDING
11.34 INFORMA PLC.
12 ABOUT US

TABLE 1 COLLOIDS (BLOOD PLASMA) REGIONAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 2 GLOBAL COLLOIDS (BLOOD PLASMA) MARKET, 2020–2030, (USD MILLION)
TABLE 3 COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE REGIONAL ANALYSIS, 2020–2030 (USD MILLION)
TABLE 4 GLOBAL COLLOIDS (BLOOD PLASMA) HISTORICAL MARKET TYPE ANALYSIS, 2015-2019, (USD MILLION)
TABLE 5 COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 6 GLOBAL COLLOIDS (BLOOD PLASMA) HISTORICAL MARKET MODE OF DELIVERY ANALYSIS, 2015-2019, (USD MILLION)
TABLE 7 COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE MODE OF DELIVERY ANALYSIS, 2020–2030 (USD MILLION)
TABLE 8 GLOBAL COLLOIDS (BLOOD PLASMA) HISTORICAL MARKET THERAPEUTIC INDICATION ANALYSIS, 2015-2019, (USD MILLION)
TABLE 9 COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE THERAPEUTIC INDICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 10 GLOBAL COLLOIDS (BLOOD PLASMA) HISTORICAL MARKET END USER ANALYSIS, 2015-2019, (USD MILLION)
TABLE 11 COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE END USER ANALYSIS, 2020–2030 (USD MILLION)
TABLE 12 GLOBAL COLLOIDS (BLOOD PLASMA) HISTORICAL MARKET APPLICATION ANALYSIS, 2015-2019, (USD MILLION)
TABLE 13 COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 14 NORTH AMERICA COLLOIDS (BLOOD PLASMA) HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 15 NORTH AMERICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 16 NORTH AMERICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE MODE OF DELIVERY ANALYSIS, 2020–2030 (USD MILLION)
TABLE 17 NORTH AMERICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE THERAPEUTIC INDICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 18 NORTH AMERICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE END USER ANALYSIS, 2020–2030 (USD MILLION)
TABLE 19 NORTH AMERICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 20 U.S. COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2015–2020
TABLE 21 U.S. COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 22 U.S. COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 23 CANADA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 24 CANADA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 25 MEXICO COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 26 MEXICO COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 27 APAC COLLOIDS (BLOOD PLASMA) HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 28 ASIA-PACIFIC COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 29 ASIA-PACIFIC COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE MODE OF DELIVERY ANALYSIS, 2020–2030 (USD MILLION)
TABLE 30 ASIA-PACIFIC COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE THERAPEUTIC INDICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 31 ASIA-PACIFIC COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE END USER ANALYSIS, 2020–2030 (USD MILLION)
TABLE 32 ASIA-PACIFIC COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 33 CHINA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 34 CHINA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 35 JAPAN COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 36 JAPAN COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 37 KOREA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 38 KOREA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 39 INDIA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 40 INDIA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 41 SOUTHEAST ASIA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 42 SOUTHEAST ASIA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA COLLOIDS (BLOOD PLASMA) HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE MODE OF DELIVERY ANALYSIS, 2020–2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE THERAPEUTIC INDICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE END USER ANALYSIS, 2020–2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 49 SAUDI ARABIA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 50 SAUDI ARABIA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 51 UAE COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 52 UAE COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 53 EGYPT COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 54 EGYPT COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 55 NIGERIA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 56 NIGERIA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 57 SOUTH AFRICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 58 SOUTH AFRICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 59 EUROPE COLLOIDS (BLOOD PLASMA) HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 60 EUROPE COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 61 EUROPE COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE MODE OF DELIVERY ANALYSIS, 2020–2030 (USD MILLION)
TABLE 62 EUROPE COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE THERAPEUTIC INDICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 63 EUROPE COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE END USER ANALYSIS, 2020–2030 (USD MILLION)
TABLE 64 EUROPE COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 65 GERMANY COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 66 GERMANY COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 67 FRANCE COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 68 FRANCE COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 69 UK COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 70 UK COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 71 RUSSIA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 72 RUSSIA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 73 ITALY COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 74 ITALY COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 75 SOUTH AMERICA COLLOIDS (BLOOD PLASMA) HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)
TABLE 76 SOUTH AMERICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)
TABLE 77 SOUTH AMERICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE MODE OF DELIVERY ANALYSIS, 2020–2030 (USD MILLION)
TABLE 78 SOUTH AMERICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE THERAPEUTIC INDICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 79 TABLE 82 SOUTH AMERICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE END USER ANALYSIS, 2020–2030 (USD MILLION)
TABLE 80 SOUTH AMERICA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)
TABLE 81 BRAZIL COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 82 BRAZIL COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 83 ARGENTINA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 84 ARGENTINA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)
TABLE 85 COLUMBIA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)
TABLE 86 COLUMBIA COLLOIDS (BLOOD PLASMA) CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)